Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
In the absence of other risk factors, do you treat the regional lymph nodes in triple negative breast cancer?
Or for that matter, offer PMRT on the basis of a patient having triple negative disease?
Answer from: Radiation Oncologist at Community Practice
At present I don't, but once Canadian and EORTC studies are published with full details available, it may change practice patterns.
Sign in or Register to read more
415
Related Questions
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
What volumes would you cover in a young patient with otherwise low risk breast cancer in whom the sentinel node failed to map and ALND was not performed?
Would you consider omitting adjuvant radiation in a very elderly patient with a small triple negative breast cancer?
How would you approach an isolated supraclavicular nodal recurrence involving the skin in a patient who has received standard chest wall and nodal radiation therapy?
Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?